Produits et services

Promoting public awareness of the need for education, research, treatment and a cure for diseases, conditions and disorders relating to seizures Providing an online forum for transmission of messages concerning diseases, conditions and disorders relating to seizures Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning diseases, conditions and disorders relating to seizures, and distributing informational course materials in connection therewith Hosting an on-line community website featuring information related to seizures; computer services, namely, creating an on-line community for registered users to participate in discussions, get feedback from their peers, form virtual communities, and engage in social networking concerning seizures; Providing a website featuring technology that enables users to search, watch, share, and comment on documents, videos, audio and other multimedia content concerning issues related to seizures Providing health information; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions relating to seizures

Produits et services

Promoting public awareness of the need for education, research, treatment and a cure for diseases, conditions and disorders relating to seizures Providing an online forum for transmission of messages concerning diseases, conditions and disorders relating to seizures Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning diseases, conditions and disorders relating to seizures, and distributing informational course materials in connection therewith Hosting an on-line community website featuring information related to seizures; computer services, namely, creating an on-line community for registered users to participate in discussions, get feedback from their peers, form virtual communities, and engage in social networking concerning seizures; Providing a website featuring technology that enables users to search, watch, share, and comment on documents, videos, audio and other multimedia content concerning issues related to seizures Providing health information; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions relating to seizures

Produits et services

Pharmaceutical products, namely, pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system

Produits et services

Medical devices, namely, drug delivery system in the nature of an oral inhaler that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system

Produits et services

Medical devices, namely, drug delivery system in the nature of an oral inhaler that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system

Produits et services

Medical devices, namely, drug delivery system in the nature of an oral inhaler that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system

Produits et services

Medical devices, namely, drug delivery system in the nature of an oral inhaler that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system

Produits et services

Medical devices, namely, drug delivery system in the nature of an oral inhaler that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system

Abrégé

Disclosed herein are methods and compositions for treating a subject with central nervous system injury. In some embodiments, a method of treating a subject with CNS injury comprises administering to the subject in need thereof a composition comprising an effective amount of a proteoglycan degrading domain. In some embodiments, administering near the site of injury comprises injecting a first amount of the composition at a first depth, and injecting a second amount of the composition at a second depth, wherein the second depth is greater than the first depth, and wherein the first depth and the second depth are at the same site of administration.

Classes IPC  ?

• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61K 6/00 - Préparations pour la technique dentaire

Abrégé

The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

Classes IPC  ?

• C07F 9/09 - Esters des acides phosphoriques
• A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• C07C 233/25 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons simples avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
• C07F 9/11 - Esters des acides phosphoriques avec des composés hydroxyalkylés sans substituant supplémentaire sur l'alkyle

Abrégé

The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance

Abrégé

The present invention provides water-soluble acetaminophen prodrugs and formulations which may be suitable for parenteral administration. Methods of treating a disease or condition responsive to acetaminophen (such as fever and/or pain) using the acetaminophen prodrugs, as well as kits, unit dosages, and combinations with additional pharmaceutical agent(s) are also provided.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
• C07F 9/09 - Esters des acides phosphoriques
• A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 49/00 - Préparations pour examen in vivo

Produits et services

Providing campaigns featuring information to promote public awareness regarding Parkinson's disease. Providing health information regarding Parkinson's disease.

Abrégé

The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present mention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 49/00 - Préparations pour examen in vivo

Abrégé

This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance

Produits et services

(1) Pharmaceutical products, namely, pharmaceutical and biological preparations for the treatment of diseases, disorders and conditions of the nervous system namely brain, movement, ocular motility, autoimmune and spinal cord diseases, disorders and conditions; pharmaceutical and biological preparations for the treatment of Parkinson's Disease, multiple sclerosis, Alzheimer's Disease and epilepsy (2) Medical devices, namely inhaler and nebulizer delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders and conditions of the nervous system

Produits et services

(1) Pharmaceutical products, namely, pharmaceutical and biological preparations for the treatment of diseases, disorders and conditions of the nervous system namely brain, movement, ocular motility, autoimmune and spinal cord diseases, disorders and conditions; pharmaceutical and biological preparations for the treatment of Parkinson's Disease, multiple sclerosis, Alzheimer's Disease and epilepsy (2) Medical devices, namely inhaler and nebulizer delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders and conditions of the nervous system

Produits et services

Pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system. Medical devices, namely, drug delivery system that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.

Produits et services

Pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system. Medical devices, namely, drug delivery system that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.

Abrégé

The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.

Classes IPC  ?

• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide

Abrégé

The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

Classes IPC  ?

• C07F 9/09 - Esters des acides phosphoriques
• C07F 9/11 - Esters des acides phosphoriques avec des composés hydroxyalkylés sans substituant supplémentaire sur l'alkyle
• C07C 233/25 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons simples avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
• A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament

Abrégé

One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/46 - Hydrolases (3)
• C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase
• C12N 9/88 - Lyases (4.)
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• C12N 9/14 - Hydrolases (3.)
• C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C07K 1/00 - Procédés généraux de préparation de peptides
• A61K 38/51 - Lyases (4)

Abrégé

The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention provides hepatoprotectant acetaminophen mutual prodrugs, which have an acetaminophen moiety covalently linked to a second moiety that may act as a hepatoprotectant against acetaminophen hepatotoxicity. Additionally, acetaminophen mutual prodrugs may have improved water solubility which may provide better suitability for parenteral and other dosage forms relative to administration of acetaminophen. Also provided are methods of treating a disease or condition that is responsive to acetaminophen (such as fever, pain and ischemic injury) using hepatoprotectant acetaminophen mutual prodrugs, as well as kits and unit dosages.

Classes IPC  ?

• C07C 323/52 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des groupes carboxyle liés au même squelette carboné ayant les atomes de soufre des groupes thio liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé
• A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate

Abrégé

Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.

Classes IPC  ?

• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• A61K 31/726 - Glycosaminoglycanes, c.-à-d. mucopolysaccharides
• A61K 31/737 - Polysaccharides sulfatés, p. ex. sulfate de chondroïtine, sulfate de dermatane
• A61K 38/51 - Lyases (4)
• C12N 9/88 - Lyases (4.)

Abrégé

The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 49/00 - Préparations pour examen in vivo

Abrégé

The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• C07K 14/475 - Facteurs de croissanceRégulateurs de croissance

Produits et services

Pharmaceutical products, namely, pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system. Medical devices, namely delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.

Produits et services

(1) Medical devices, namely inhaler and nebulizer delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders and conditions of the nervous system

Produits et services

(1) Pharmaceutical products, namely, pharmaceutical and biological preparations for the treatment of diseases, disorders and conditions of the nervous system namely brain, movement, ocular motility, autoimmune and spinal cord diseases, disorders and conditions; pharmaceutical and biological preparations for the treatment of Parkinson's Disease, multiple sclerosis, Alzheimer's Disease and epilepsy.

Produits et services

Pharmaceutical products, namely, pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system. Medical devices, namely delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.

Produits et services

Pharmaceutical products, namely, pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system. Medical devices, namely delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.

Produits et services

(1) Pharmaceutical products, namely, pharmaceutical and biological preparations for the treatment of diseases, disorders and conditions of the nervous system namely brain, movement, ocular motility, autoimmune and spinal cord diseases, disorders and conditions; pharmaceutical and biological preparations for the treatment of Parkinson's Disease, multiple sclerosis, Alzheimer's Disease and epilepsy

Abrégé

The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.

Classes IPC  ?

• C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• C12N 9/88 - Lyases (4.)
• C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• C12N 9/14 - Hydrolases (3.)
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C07K 1/00 - Procédés généraux de préparation de peptides
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61K 38/46 - Hydrolases (3)
• C12N 9/88 - Lyases (4.)
• C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• C12N 9/14 - Hydrolases (3.)
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C07K 1/00 - Procédés généraux de préparation de peptides
• A61K 38/51 - Lyases (4)

Abrégé

Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.

Classes IPC  ?

• A61K 38/51 - Lyases (4)
• C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
• C12N 9/88 - Lyases (4.)

Produits et services

Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions. Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions and distributing informational course materials in connection therewith. Providing health information; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions.

Produits et services

Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions. Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions and distributing informational course materials in connection therewith. Providing health information; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions.

Produits et services

Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions. Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions and distributing informational course materials in connection therewith. Providing health information; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions.

Produits et services

(1) Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions of the central nervous system; Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions of the central nervous system and distributing informational course materials in connection therewith; Providing health information about issues related to diseases, disorders and conditions of the central nervous system; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions of the central nervous system.

Produits et services

(1) Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions of the central nervous system; Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions of the central nervous system and distributing informational course materials in connection therewith; Providing health information about issues related to diseases, disorders and conditions of the central nervous system; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions of the central nervous system.

Produits et services

(1) Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions of the central nervous system; Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions of the central nervous system and distributing informational course materials in connection therewith; Providing health information about issues related to diseases, disorders and conditions of the central nervous system; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions of the central nervous system.

Abrégé

The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with stroke-related impairments, in particular, in patients with sensorimotor impairments resulting from certain types of stroke.

Classes IPC  ?

• A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

Provided herein are methods and compositions for treatment of patients with Parkinson's disease and, in particular, motor impairments in patients with Parkinson's disease, using an aminopyridine.

Classes IPC  ?

• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
• A61P 25/16 - Antiparkinsoniens

Produits et services

(1) Pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system, namely, epileptic seizure clusters and acute repetitive seizures.

Abrégé

Disclosed herein is use of one or more aminopyridines in methods and compositions for improving walking capacity in patients with multiple sclerosis.

Classes IPC  ?

• A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Produits et services

Pharmaceutical products; pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.

Abrégé

The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance

Abrégé

The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• C07K 14/475 - Facteurs de croissanceRégulateurs de croissance

Abrégé

Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The disclosure provides compositions and methods for preventing, ameliorating a sign or symptom of, or treating peripheral nerve injury.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques

Abrégé

Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.

Classes IPC  ?

• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
• A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p. ex. chorée, dyskinésie

Abrégé

Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with a stroke-related impairment, in particular, in patients with a stroke-related sensorimotor impairment.

Classes IPC  ?

• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

Acetaminophen conjugates are provided, which have an acetaminophen moiety covalently linked to a second moiety. The conjugates provided may have one or more advantageous properties, including increased water solubility as compared to acetaminophen, reduced toxicity profile as compared to acetaminophen and an altered pharmacokinetic profile. Formulations comprising the conjugates are also provided, as are methods of using the conjugates and kits comprising the conjugates.

Classes IPC  ?

• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse

Produits et services

Pharmaceutical and biological compositions used in the treatment of neurological diseases, disorders or conditions.

Produits et services

Pharmaceutical and biological compositions used in the treatment of neurological diseases, disorders or conditions.

Abrégé

The present invention generally relates to intranasal pharmaceutical compositions comprising a benzodiazepine and methods of use thereof that can provide a therapeutic effect without a decrease in blood pressure and/or pulse after administration of the pharmaceutical composition.

Classes IPC  ?

• A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
• A61K 31/5517 - 1,4-Benzodiazépines, p. ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p. ex. imidazobenzodiazépines, triazolam
• A61K 9/12 - AérosolsMousses

Abrégé

Disclosed herein is the use of aminopyridines, such as 3-aminopyridine, 4-aminopyridine or 3,4-diaminopyridine, in the management and treatment of cerebral palsy patients of all ages.

Classes IPC  ?

• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
• A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p. ex. chorée, dyskinésie

Abrégé

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

Classes IPC  ?

• A61K 49/00 - Préparations pour examen in vivo
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide

Abrégé

This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance

Produits et services

(1) Pharmaceutical preparations for the treatment of function in neurological, neurotrauma, autoimmune, neuromuscular, demyelinating, cardiac and neurodegenerative diseases and disorders, namely, spinal cord injuries, multiple sclerosis, stroke, brain injury, Guillame-Barre Syndrome, Charcot Marie Tooth Syndrome, Parkinson's Disease, seizure disorders, cerebral palsy, muscular dystrophy, Lambert-Eaton, spasticity, neuropathic pain, Alzheimer's Disease, anterior horn cell diseases, cluster headache, migraine, peripheral neuropathy, diabetic neuropathy, congestive heart failure, myocardial infarction and mononeuritus multiplex.

Abrégé

Embodiments of the invention are directed to use of neuregulins to prevent or treat peripheral nerve injury, to attenuate, ameliorate or avoid the loss of peripheral nerve function.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques

Abrégé

The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.

Classes IPC  ?

• A01N 37/18 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe —CO—N, p. ex. amides ou imides d'acide carboxyliqueLeurs thio-analogues
• A61K 38/00 - Préparations médicinales contenant des peptides

Produits et services

Pharmaceutical and biological preparations used in the treatment of neurological diseases, disorders or conditions Promoting public awareness of the need for education, research, treatment and a cure for neurological and mobility diseases and disorders Providing an online forum for transmission of messages concerning issues related to neurological diseases, disorders or conditions Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to neurological diseases, disorders and conditions and distributing informational course materials in connection therewith Hosting an on-line community website featuring information related to neurologic disorders; computer services, namely, creating an on-line community for registered users to participate in discussions, get feedback from their peers, form virtual communities, and engage in social networking concerning issues related to neurologic disorders; Providing a website featuring technology that enables users to search, watch, share, and comment on documents, videos, audio and other multimedia content concerning issues related to neurologic disorders Providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions

Produits et services

Pharmaceutical and biological preparations used in the treatment of neurological diseases, disorders or conditions Promoting public awareness of the need for education, research, treatment and a cure for neurological and mobility diseases and disorders Providing an online forum for transmission of messages concerning issues related to neurological diseases, disorders or conditions Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to neurological diseases, disorders and conditions and distributing informational course materials in connection therewith Hosting an on-line community website featuring information related to neurologic disorders; computer services, namely, creating an on-line community for registered users to participate in discussions, get feedback from their peers, form virtual communities, and engage in social networking concerning issues related to neurologic disorders; Providing a website featuring technology that enables users to search, watch, share, and comment on documents, videos, audio and other multimedia content concerning issues related to neurologic disorders Providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions

Abrégé

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro -cognitive impairments and related neuro- psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.

Classes IPC  ?

• A01N 43/40 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons
• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés

Abrégé

The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/46 - Hydrolases (3)
• C12N 9/88 - Lyases (4.)
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C07K 1/00 - Procédés généraux de préparation de peptides
• A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau

Abrégé

One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/46 - Hydrolases (3)
• C12N 9/88 - Lyases (4.)
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C07K 1/00 - Procédés généraux de préparation de peptides

Abrégé

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.

Classes IPC  ?

• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime

Abrégé

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.

Classes IPC  ?

• A61K 31/52 - Purines, p. ex. adénine

Abrégé

A process for determining responders in clinical testing environments that involves, inter alia, detecting treatment response through the use of small numbers of measurements of randomly varying outcome variables in individual clinical trial subjects, and by analyzing the measurements in such a way as to eliminate troublesome variables, such as a spontaneous population variability.

Classes IPC  ?

• G06Q 50/00 - Technologies de l’information et de la communication [TIC] spécialement adaptées à la mise en œuvre des procédés d’affaires d’un secteur particulier d’activité économique, p. ex. aux services d’utilité publique ou au tourisme

Abrégé

The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.

Classes IPC  ?

• A01N 43/40 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons
• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés

Abrégé

This invention relates to treatment of neuroinjury in a post- acute window or in a chronic period following neuroinjury.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance

Abrégé

The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques

Produits et services

Pharmaceutical and biological preparations, products and formulations used in the treatment of spinal cord injuries, multiple sclerosis and other neurological or musculoskeletal diseases, disorders or conditions.

Abrégé

An aspect of the present invention relates to stable formulations of chondroitinase and to methods of purifying chondroitinase. The methods of purifying chondroitinase includes the steps of extracting the enzyme from a cell, separating the chondroitinase from the crude cell extract using cation-exchange chromatography, removing impurities through gel filtration chromatography, and removing endotoxin through an anion-exchange membrane to produce a purified chondroitinase.

Classes IPC  ?

• A61K 38/46 - Hydrolases (3)
• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide

Abrégé

The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designed to treat a damaged heart in a patient.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C12N 5/08 -
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

Classes IPC  ?

• C12N 9/88 - Lyases (4.)
• C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

Classes IPC  ?

• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61K 38/46 - Hydrolases (3)
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide

Abrégé

Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Classes IPC  ?

• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
• A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue

Abrégé

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

Classes IPC  ?

• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
• A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue

Produits et services

Pharmaceutical preparations used in the treatment of spinal cord injuries, multiple sclerosis and other neurological disorders or conditions

Produits et services

pharmaceuticals.

Abrégé

A pharmaceutical composition which comprises a therapeutically effect amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis.

Classes IPC  ?

• A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
• C40B 30/06 - Procédés de criblage des bibliothèques en mesurant les effets sur des cellules, des tissus ou des organismes vivants
• G01N 33/15 - Préparations médicinales